- Biogen’s mixed Alzheimer’s data; Two new startups launch; and moreWelcome back to another edition of Endpoints Weekly! We hope you all have been staying safe indoors as the Canadian wildfires blanketed much of the US Northeast this week. Hopefully things calm dow…Endpoints · 9d ago↗ source
- ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsAfter Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.Fierce Biotech · 9d ago↗ source
- Midsized biotechs press White House to drop CMS pricing rulesA number of midsized biotech companies have met with White House and HHS officials in the last week, presenting their case for why two pending CMS pricing models could hinder their business and sho…